Astrazeneca Ab

Navidea Biopharmaceuticals, Inc.

Ylva Gravenfors

Gunnar Nordvall

Daniel Sohn

David Wensbo

Can Slivo

Jonas Malmstrom

David Pyring

Catrin Jonasson

Peter Strom

Stefan Von Berg

Jörg Holenz

Alexander Minidis

Jenny Viklund

Johan Bylund

Maria E Ek

Karl S A Vallin

The invention provides compounds of formula (I) wherein R, R, L, L, G, G, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1. 

Bis-(sulfonylamino) derivatives for use in therapy

The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.

Heteroaryl substituted benzothiazoles

The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: [Chemical formula should be inserted here. Please see paper copy] and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. 

Growing community of inventors

Sodertalje, Sweden

Ylva Gravenfors